DAX19.885 -0,4%ESt504.862 -0,3%Top 10 Crypto15,18 +0,5%Dow42.840 +1,2%Nas19.573 +1,0%Bitcoin91.576 -1,7%Euro1,0434 +0,7%Öl72,98 +0,4%Gold2.621 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Tesla A1CX3T Volkswagen (VW) vz. 766403 Sirius XM A1W8XE Palantir A2QA4J Allianz 840400 Rheinmetall 703000 Amazon 906866 Bayer BAY001 Apple 865985 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 MicroStrategy 722713 ASML NV A1J4U4
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen mit versöhnlichem Wochenausklang -- DAX geht tiefer ins Wochenende -- Novo Nordisk-Therapie enttäuscht in Studie -- Bitcoin fällt tief -- D-Wave, FedEx im Fokus
Top News
Goldpreis, Weizenpreis & Co.: Wie sich die Rohstoffkurse am Sonntagabend entwickeln Goldpreis, Weizenpreis & Co.: Wie sich die Rohstoffkurse am Sonntagabend entwickeln
Sperre für TikTok: Albanien will Zugang für ein Jahr sperren - Trump will TikTok vielleicht noch eine Weile behalten Sperre für TikTok: Albanien will Zugang für ein Jahr sperren - Trump will TikTok vielleicht noch eine Weile behalten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Phaxiam Therapeutics Aktie

NeuKaufenVerkaufen
1,62 EUR -0,02 EUR -1,10 %
FSE
1,74 EUR +0,01 EUR +0,58 %
PAR
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.17,31 Mio. EUR

Div. Rendite0,00%

WKNA3EJH8

ISINFR001400K4B1

Phaxiam Therapeutics Aktien News

DatumMeistgelesen
GlobeNewswirePHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024
GlobeNewswirePHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
GlobeNewswirePHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
Wer­bungPhaxiam Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswirePHAXIAM Reports Third-Quarter 2024 Financial Information
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
GlobeNewswirePHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
GlobeNewswirePHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
GlobeNewswirePHAXIAM Provides Business and Financial Update For the First Half of 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – July 1, 2024
GlobeNewswireResults of the Combined General Meeting of 28 June 2024
GlobeNewswirePHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
GlobeNewswirePHAXIAM provides Business and Financial Update for the First Quarter of 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
GlobeNewswirePHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
GlobeNewswirePHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
GlobeNewswirePHAXIAM Announces 2023 Full-Year Results and Provides Business Update
GlobeNewswirePHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
GlobeNewswirePHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024
GlobeNewswirePHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
GlobeNewswirePHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
GlobeNewswirePHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
GlobeNewswireTP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation
GlobeNewswireMonthly information related to total number of voting rights and shares composing the share capital _September 30, 2023

Phaxiam Therapeutics News

Phaxiam Therapeutics News: auf dieser Seite finden Sie alle Phaxiam Therapeutics News und Nachrichten zur Phaxiam Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Phaxiam Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Phaxiam Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.